Cardiovascular Disease

Urokinase product ThromboClear entering manufacturing stage

Published in Vaccine Weekly, December 22nd, 2004

Microbix Biosystems Inc. (TSX: MBX) announced that together with its partner Genpharm Inc., all key manufacturing facilities are nearing completion and the ThromboClear project is entering the manufacturing stage for submission.

"This milestone marks a major turning point for our product commercialization plan," said William J. Gastle, President and CEO. "Initial manufacturing runs have been completed successfully and we hope to finish the next phase at an early date," he continued.

The market potential for urokinase is believed to be significant based on market analysis and discussions with physicians. "Hospitals need better access to affordable...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-12-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry